Phase 3b open-label RCT in 251 pregnant women without HIV starting PrEP in the second trimester (dapivirine ring vs oral tenofovir-emtricitabine): 11% had serious or grade ≥3 adverse events, none product-related; 94% of births were at term.
RCTn = 251
Mhlanga et al. Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trial